title: Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors.
abstract: BACKGROUND
  The advanced renal cell carcinoma (RCC) affects patients mainly ∼60 years of age and who may have an active sex life. The objective of the study was to investigate possible sexual disorders in a male population with advanced RCC treated with a molecular targeted therapy (MTT).
  
  
  METHODS
  Thirty-eight male patients with a stabilized advanced RCC on MTT were proposed a personal interview about their sexual life, filled in the International Index of Erectile Function (IIEF) auto-questionnaire, and were reassessed if the treatment was modified.
  
  
  RESULTS
  This is the first evaluation of sexual life while on MTT. For 64% of the patients (median age 59 years, treatment duration 12 months), the quality of their sexual life was considered important. The scores of the IIEF were reduced from 30% to 60% in erectile function, intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction. The erectile dysfunction was more severe in the MTT population compared with age-stratified general or urological populations. The disorders were reversible in a few cases after treatment interruption.
  
  
  CONCLUSIONS
  Patients on MTT for an advanced RCC experience a decline of sexual activity. Onco-urologists should systematically inform, screen, initiate management, and refer patients to sexual medicine physicians.
authors.affiliation: Department of Medicine, Institut Gustave Roussy, Villejuif, France. thomas.bessede@gmail.com
authors.forename: T
authors.initials: T
authors.lastname: Bessede
authors.forename: C
authors.initials: C
authors.lastname: Massard
authors.forename: B
authors.initials: B
authors.lastname: Albouy
authors.forename: S
authors.initials: S
authors.lastname: Leborgne
authors.forename: M
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: S
authors.initials: S
authors.lastname: Droupy
authors.forename: J-J
authors.initials: JJ
authors.lastname: Patard
authors.forename: K
authors.initials: K
authors.lastname: Fizazi
authors.forename: B
authors.initials: B
authors.lastname: Escudier
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology*; D007172:Erectile Dysfunction / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D012189:Retrospective Studies; D012725:Sexual Behavior / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors